2月11日，健康160(02656)股价在低开震荡约1个小时后突然大幅跳水，半个小时内，公司股价从约90港元跳水跌至最 低55港元，盘中股价振幅接近40%，最终公司当日收跌30.73%。公司股价由此回吐年内多数涨幅，总市值一度跌穿 200亿港元。 从发行方案来看，华芢生物在发行上采用了"机制B+无基石"方式，倚赖机构投资者作"市场锚定"。如今看来，该方案 对于一家基本面有待提高的未盈利18A而言或许有些激进，但对于当时的华芢生物来说，只是"踩着石头过河"，而这 条路正是健康160踩出来的。 靠"机制B+无基石"博进港股通 其实对比华芢生物和健康160的IPO发行方案，投资者不难看出二者间的相似之处。 自去年8月港交所港股发布IPO新规以来，不少企业把公开配售压到10%的下限，"人为制造"极致缩量的流通盘，并形 成以机构、基石和锚定投资者为主的发行格局，为公司上市开局"保价护航"。据智通财经APP了解，在选择"机制B"的 基础上，两家公司均选择了"无基石"方案，仅设有"绿鞋"机制。如此一来，其高达90%的国际配售比例在缺乏基石锁 仓情况下，基本只能倚赖机构投资者作"市场锚定"。 根据发行计划，健康160全球发售 ...

Core Viewpoint - The "Three-Year Action Plan for Supporting the Transformation and Upgrading of Advanced Manufacturing Industry in Shanghai (2026-2028)" aims to accelerate the establishment of a modern industrial system centered on advanced manufacturing, promoting green and digital transformation across enterprises of all sizes [1][2]. Group 1: Action Plan Overview - The action plan includes four major actions and 17 measures to enhance the development of advanced manufacturing in Shanghai [1]. - By 2028, Shanghai aims to add 100 manufacturing enterprises with an annual output value exceeding 1 billion yuan and increase the number of industrial enterprises above designated size by 500 [1]. Group 2: Development Paths - The plan outlines three development paths: - For traditional advantageous industries, it emphasizes "optimization and enhancement" [1]. - For leading industries, it promotes "strategic guidance" [1]. - For key and emerging industries, it focuses on "expansion and development" [1]. Group 3: Innovation and Support Measures - The action plan supports enterprises in high-level R&D and high-value product transformation, addressing industry pain points and overcoming key core technologies [2]. - Financial support includes one-time subsidies for R&D investments, with amounts varying based on the level of investment [2]. Group 4: Financial Incentives - Companies investing in technology transformation projects can receive interest subsidies on loans or equipment financing leases, with a maximum subsidy of 20 million yuan [3]. - Additional rewards are available for energy-saving upgrades and for companies recognized as national green factories [3].

Core Insights - The GDP performance of Jinan's eastern districts has shown significant growth, with a total GDP of 919.39 billion yuan, accounting for 64.7% of the city's total GDP [1] - The main urban districts (Lixia, High-tech, Licheng, and Zhangqiu) collectively achieved a GDP of 777.72 billion yuan, with growth rates surpassing the city average of 5.4% [1] Group 1: Economic Performance - The eastern region's GDP growth is driven by the "East Strong" strategy, with the main urban districts showing robust performance: High-tech at 7.61%, Zhangqiu at 5.9%, Lixia at 5.6%, and Licheng at 5.1% [1] - The growth rate of the starting districts is 10.4%, but the larger economic base of the main urban districts makes their growth more challenging [1] Group 2: Factors Contributing to Growth - The Qilu Innovation Corridor has created a significant axis effect, linking major research platforms and facilitating the transition from research to industrialization [2] - The advantages of national-level development zones, such as the Jinan High-tech Zone and Zhangqiu Ming Shui Economic and Technological Development Zone, have fostered a collaborative environment for high-end industries [2] - The integration of transportation hubs, including the expansion of Yaoqian International Airport and the development of logistics projects, enhances the eastern region's economic capabilities [2] Group 3: Manufacturing and Industrial Base - The manufacturing sector is a strong foundation for economic growth, with significant increases in industrial output: High-tech at 15.6% and Zhangqiu at 9.5% [3] - The solid manufacturing base in Zhangqiu, characterized by a complete industrial chain and active private economy, supports the region's economic resilience [3] Group 4: Future Growth Potential - The eastern region has vast growth potential, with ongoing projects in high-tech zones and specialized industrial parks [5] - Infrastructure developments, such as the second phase of Yaoqian Airport and the opening of Metro Line 8, will enhance connectivity and integration with the main city [5] - The influx of talent from local universities will strengthen the innovation capabilities of the Qilu Innovation Corridor [6]

Core Viewpoint - The company Teva Biopharma (688278.SH) has demonstrated robust growth in its operating performance, achieving record highs in revenue and net profit for 2025, driven by stable sales of key products and new product approvals [1][2]. Financial Performance - In 2025, Teva Biopharma reported revenue of 3.696 billion yuan, a year-on-year increase of 31.18%, and a net profit attributable to shareholders of 1.038 billion yuan, marking a 25.38% increase and the first time surpassing the 1 billion yuan mark [2][4]. - The company achieved revenue and net profit of 2.480 billion yuan and 666 million yuan respectively in the first three quarters of 2025, reflecting year-on-year growth of 26.85% and 20.21% [2]. - In the fourth quarter of 2025, revenue and net profit reached 1.216 billion yuan and 372 million yuan, showing significant growth of 41.07% and 36.26% year-on-year [2][3]. Consistent Growth - Teva Biopharma has experienced continuous growth in revenue and net profit for eight consecutive years from 2018 to 2025, with revenue increasing from 448 million yuan in 2018 to over 3 billion yuan in 2025 [1][3]. - The net profit has also shown substantial growth, increasing from 16 million yuan in 2018 to 1.038 billion yuan in 2025, representing a growth of 787.18% compared to 2020 [4]. Product Development - The company focuses on the clinical cure of hepatitis B, having launched six drugs and one electronic pen injector by June 2025 [1][6]. - Teva Biopharma's key product, Pegbavirin, is recognized as the first drug globally targeting clinical cure for hepatitis B, further solidifying its position in the market [3][6]. Research and Development - R&D investment has been on the rise, with 312 million yuan spent in the first three quarters of 2025, reflecting a year-on-year increase of 38.67% [1][7]. - The company has completed nine major new drug creation projects under national technology initiatives, with several innovative drugs currently in clinical research [7]. Shareholder Returns - Since its listing in 2020, Teva Biopharma has consistently returned value to shareholders, distributing a total of 567 million yuan in dividends over five years, which is 1.5 times its equity financing amount [1][7].

Core Insights - The provincial strategic emerging industry fund cluster held its first meeting of 2026, signing agreements for five specialized funds with a total scale of 69.1 billion yuan, raising the total scale of the fund cluster to 275.6 billion yuan [1][2] Group 1: Fund Details - The Long Triangle Venture Capital Guidance Fund, with a scale of 55.1 billion yuan, is a key highlight of the signing, aimed at supporting the integration development strategy of the Yangtze River Delta region [1] - The provincial fund for high-quality development of new industries, initiated by the High Investment Group, has a scale of 10 billion yuan and focuses on sectors such as biomedicine, new energy, integrated circuits, artificial intelligence, and robotics [1] - The Jiangsu Province Suhao Modern Service Industry Innovation Development Fund aims to promote the deep integration of modern service industries with strategic emerging industries, with a target scale of 10 billion yuan and an initial phase of 2 billion yuan [1] Group 2: Fund Cluster Achievements - The provincial strategic emerging industry fund cluster has established a total of 46 specialized funds with a cumulative scale of 176 billion yuan, completing decision-making processes for 50 sub-funds totaling 49.6 billion yuan [2] - The fund cluster has invested in over 200 projects, leading to direct equity investments exceeding 20 billion yuan, with two direct investment projects achieving IPO listings [2]

Core Insights - Singapore attracted 14.2 billion SGD in fixed asset investments in 2025, marking a 5.2% year-on-year increase despite global geopolitical and economic challenges [1] - Chinese investments surged, increasing from 2.5% in 2024 to 20.6% in 2025, surpassing the US to become Singapore's second-largest investment source after Europe [1] Investment Structure - Of the 14.2 billion SGD in fixed asset investment commitments, approximately 12.1 billion SGD came from manufacturing-related projects, accounting for 85% [2] - Semiconductor manufacturing led the investments, contributing 33% of the fixed asset investments, driven by the explosive growth in global AI demand [2] - Investments in biopharmaceutical manufacturing, specialty chemicals, sustainable materials, and aerospace maintenance also saw significant interest from Chinese enterprises [2] Strategic Shifts in Operations - 55% of surveyed Chinese enterprises rated Singapore's business environment as "excellent," with public services and financial systems being key attractions [3] - The strategic positioning of Chinese enterprises in Singapore has evolved from a "springboard" to a "regional headquarters hub," with over 70% viewing the Johor-Singapore Economic Zone as vital for capacity expansion and cost management [3] Full Industry Chain Ecosystem - Chinese companies are establishing a comprehensive industry chain ecosystem in Singapore, with firms like ByteDance and Ant Group setting up regional headquarters [4] - This integrated model of "R&D + manufacturing + sales + financial management" signifies a shift from simple market expansion to global value chain restructuring [4] - Singapore's role as an international financial center facilitates comprehensive financial services for Chinese enterprises, reducing reliance on the US dollar system [4] Regional Economic Integration - The influx of Chinese investments in Singapore reflects the accelerating economic integration between China and Southeast Asia [5] - The model of "Singapore base + ASEAN manufacturing + global sales" is being replicated in countries like Vietnam and Malaysia, reshaping the global supply chain geography [5] Future Outlook - The investment trend from Chinese enterprises in Singapore is expected to continue, driven by factors such as the advancement of the China-Singapore Free Trade Agreement and Singapore's role in digital currency trials [6] - Despite potential challenges, the Singapore model remains a preferred strategy for Chinese enterprises to navigate trade barriers and expand into global markets [6]

Core Viewpoint - Shenzhen aims to enhance its modern industrial system by implementing the "20+8" strategic emerging industry cluster and future industry policy system 3.0 by 2026, targeting a growth of over 7% in the added value of strategic emerging industries [1] Group 1: Strategic Emerging Industries - By 2025, the added value of Shenzhen's strategic emerging industries is projected to reach 1.67 trillion yuan, accounting for 43% of the regional GDP, with 1,333 national-level specialized and innovative "little giant" enterprises [1] - Shenzhen will focus on enhancing the development capabilities of key industries such as new generation electronic information, new energy vehicles, and semiconductors, while accelerating the construction of major integrated circuit manufacturing projects [2] - The city plans to expand its low-altitude economy, biomedicine, and high-performance materials sectors, promoting deep collaboration in manufacturing and service support [2] Group 2: Innovation and Talent Attraction - Shenzhen will accelerate the construction of key research projects in various fields, including integrated circuits and advanced materials, with over 150 major R&D projects planned [3] - The city aims to increase R&D investment by over 10% this year and attract high-level talent in key technology sectors through initiatives like the "Million Talents Gathering" plan [3] - Shenzhen plans to establish a robust ecosystem of over 10,000 innovation and investment funds, supporting high-growth enterprises [3] Group 3: Urban Development and Infrastructure - Shenzhen will develop new urban areas with a focus on integrating education, research, and finance, while enhancing infrastructure such as the extension of Metro Line 13 [4] - The city aims to become a global leader in smart city development, with plans to add 2,000 5G-A base stations and improve IoT sensing platforms [4] Group 4: Consumer Market and Economic Growth - Expanding domestic demand and promoting consumption will be a priority for Shenzhen in 2026, with initiatives to foster new consumption growth points in AI and other sectors [6] - The city plans to develop world-class commercial districts and enhance the retail environment, including the addition of over 500 duty-free shops [7] - Shenzhen's retail sales are expected to stabilize at over 1 trillion yuan during the "14th Five-Year Plan" period, with significant growth in the wholesale and retail sectors [7] Group 5: Tourism and Cultural Development - Shenzhen aims to become a world-class tourist destination by developing various attractions and enhancing the overall tourism experience [5][6] - The city will focus on integrating sports and technology to create immersive consumer experiences in the sports sector [5] - Recommendations include improving the accommodation ecosystem to meet diverse consumer needs, enhancing the overall tourism infrastructure [8]

Core Viewpoint - Advanced Biomed Inc. has made a significant asset sale, resulting in notable stock price volatility, while the company's fundamentals remain in a state of no revenue generation and ongoing losses [1]. Recent Events - On December 23, 2025, the company signed an agreement to sell 100% of its wholly-owned subsidiary Advanced Biomed (HK) Limited for a total consideration of $23,000, which includes all intellectual property owned by the subsidiary. The CEO stated that this sale is part of a strategic adjustment to respond to changes in the regulatory environment in China, with future clinical trials to be focused on the Taiwan subsidiary [2]. Stock Performance - The stock exhibited high volatility from December 2025 to early January 2026. For instance, on December 26, 2025, the stock price dropped by 11.44%, while on January 5, 2026, it rebounded with a 5.26% increase. This volatility may reflect market reactions to the company's actions and overall trading sentiment [3]. Financial Performance - According to the latest financial report, the company reported zero revenue, a net loss of $12,925.94, earnings per share of $0, and a negative price-to-earnings ratio ranging from -1.89 to -2.14, indicating that the company is still in a state of no revenue generation and losses [4]. Institutional Views - As of January 8, 2026, there are no institutional investment ratings or recommendations available for the stock [5].

Core Viewpoint - The South Korean Ministry of Finance and Economy is focusing on expanding the export scale of the bio-health industry, including pharmaceuticals, medical devices, and cosmetics, through a "one-stop export" support initiative [1] Group 1: Export Support Initiatives - The "One-Stop Export 119" meeting was held to assist companies in overcoming export rule restrictions and operational difficulties caused by external environmental changes [1] - The government aims to create customized support plans and promote institutional reforms to enhance the export capabilities of the bio-health sector [1] Group 2: Industry Performance - In the previous year, South Korea's bio-health industry achieved a record export value of $27.9 billion [1] - The government is targeting to set new export records by 2026, indicating a strong growth trajectory for the industry [1]

Group 1: Core Insights - The article highlights the absence of significant announcements from a company named "Shengyan Bio" as of February 11, 2026 [1] - It points out notable developments in the biopharmaceutical sector involving companies with similar names [1] Group 2: Stock Performance - Maiwei Bio-U announced a global strategic cooperation agreement with Sentonix on January 7, 2026, to jointly develop innovative drugs for neurodegenerative diseases [2] Group 3: Business Performance - Rongchang Bio's 2025 earnings forecast indicates a revenue increase of approximately 89% year-on-year, achieving profitability. The company has multiple new drug indication applications accepted, with expected market attention in 2026 [3] Group 4: Strategic Initiatives - Liankang Biotechnology Group signed a tripartite strategic cooperation agreement with Wenzhou Medical University National Engineering Research Center and the People's Government of Ouhai District, Wenzhou, on December 30, 2025, to enhance its R&D pipeline in skin, ophthalmology, and metabolic diseases [4]